Ibrahim H, et al. - Via this retrospective analysis of consecutive patients (n = 266) undergoing transcatheter aortic valve replacement (TAVR), researchers investigated if postprocedural thrombocytopenia could be prevented by preprocedural P2Y₁₂ inhibition, which was defined as preprocedure clopidogrel load ≥300 mg or maintenance P2Y₁₂ inhibitor therapy. They excluded 8 patients who did not consent for the registry, 14 patients with baseline severe thrombocytopenia (<90 × 10³ platelets/μL) and 4 patients without baseline platelet count. According to the findings, a reduction in platelet count post-TAVR was less likely in patients who received preprocedural P2Y₁₂ inhibition before TAVR.